Abstract Library

#4349 Challenging management of ductal adenocarcinoma of the prostate with neuroendocrine differentiation: A case report

Introduction: Ductal adenocarcinoma of the prostate is a rare subtype of prostate cancer that arises from the ducts of the prostate gland. It is characterised by distinct histological features and a more aggressive clinical course. Neuroendocrine differentiation within this subtype is associated with a more aggressive phenotype and can lead to resistance to conventional androgen deprivation therapies.

Conference:

Presenting Author:

Authors: Zerrouk D, Boukerzaza I, Laouar N, Kassama Z, Mansouri F,

Keywords: neuroendocrine prostate cancer, progression, multidisciplinary approach,

#3512 Genetic, epigenetic and/or transcriptional profiling of 14q genes, MAX and MEG3 in pituitary neuroendocrine tumors

Introduction: Recent studies have identified a growing series of susceptibility genes for pituitary neuroendocrine tumors (PitNETs) and pheochromocytomas/paragangliomas (PPGL). Some of these genes (e.g., SDH genes) have be specifically associated with the development of these pathologies.

Conference:

Presenting Author: Ibáñez Costa A

Authors: Ibáñez-Costa A, Letón R, Rivero-Cortés E, Álvarez-Escolá C, Rodriguez Poyo-Guerrero P,

Keywords: pituitary tumor, epigenetics, MAX, genomics,

#3363 Neuroendocrine prostate cancer: About 4 cases

Introduction: Neuroendocrine tumors of the prostate are rare entities with a very poor prognosis. They can be pure (small or large cell neuroendocrine carcinoma) or mixed. They do not express prostate specific antigen (PSA) or the androgen receptor. Their treatment is based only on chemotherapy based on platinum for the advanced forms.

Conference:

Presenting Author:

Authors: Kehili H, Bengueddache A, Boumansour N, Kaid M, Benabdellah H,

Keywords: neuroendocrine prostate, poor prognosis,

#2746 Immunohistochemical Biomarker Expression in Gastro-Entero-Pancreatic Neuroendocrine Tumors at ENETS Centre of Excellence, University Hospital Zurich, Switzerland

Introduction: Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are a heterogeneous tumor entity with respect to biological behaviour and prognosis. This makes diagnosis and treatment a major challenge.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Siebenhüner A

Authors: Duschek S, Weber A, Curioni-Fontecedro A, Siebenhüner A,

Keywords: Biomarker, immunohistochemistry, GEP-NET, TMA, Prognosis, hormone receptor,

#1033 Androgens Regulate SMAD Ubiquitination Regulatory Factor-1 Expression and Prostate Cancer Cell Invasion

Introduction: Prostate cancer is the most commonly diagnosed male cancer and is a hormone-driven disease. Androgens have been recognized as a major promoter of PCa development and progression. However, the mechanism of androgen action in PCa, especially in PCa cell invasion remains largely unclear. SMAD ubiquitination regulatory factor-1 (SMURF1) is a C2-WW-HECT-domain E3 ubiquitin ligase that plays important roles in cancer cell metastasis. Whether there is a relationship between androgens and SMURF1 express is not known.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Xiaokun G

Authors: Xiaokun G, Guixia W,

Keywords: Androgen, AR, SMURF1, prostate cancer, invasion,